MedTrace Logo

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

NCT06220318 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2025-11-28

No results posted yet for this study

Summary

This is a phase I/II non-randomized, open-label, single-arm, multicenter study to evaluate the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors.

Conditions

Interventions

DRUG

C019199

The C019199 will be taken orally, once a day

DRUG

Sintilimab

Sintilimab will be administrated with intravenous infusion, 200mg, every 3 weeks.

Sponsors & Collaborators

  • Fujian Haixi Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • FENG YE · The First Affiliated Hospital of Xiamen University

  • YONGCHANG ZHANG · Hunan Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-19
Primary Completion
2026-08-30
Completion
2026-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06220318 on ClinicalTrials.gov